As clinical research continues to deepen and drug applications become more widespread, the position of SGLT-2 inhibitors in the management of HF complicated by T2DM will be further consolidated, providing more potent treatment options for clinicians and patients. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.